Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Lisata Therapeutics, Inc. (LSTA)
USD3.75
+0.04 (+1.08%)
US NASDAQ Healthcare Biotechnology
Address
110 Allen Road 7920
Basking Ridge, NJ, US
Basking Ridge, NJ, US
CEO
David J. Mazzo
Website
lisata.com
IPO
1999-03-01
CIK 320017 ISIN US1280583022
Also trades on
NASDAQ Capital Market · CLBS (USD)
NASDAQ Capital Market · LSTA (USD)
Description
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on pioneering and bringing to market cellular therapies. These treatments are designed to either reverse disease progression or facilitate the repair of damaged bodily tissues. The company's product portfolio features several notable candidates: HONEDRA, which has received SAKIGAKE designation and is presently in Phase II clinical trials for critical limb ischemia; XOWNA, currently undergoing Phase IIb testing for coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy aimed at individuals with chronic kidney disease who are not yet on dialysis. Founded in 1980 and based in Basking Ridge, New Jersey, the company was initially known as NeoStem, Inc., then rebranded as Caladrius Biosciences, Inc. in June 2015, before assuming its present identity as Lisata Therapeutics, Inc. on September 15, 2022.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD3.75
+0.04 (+1.08%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
114.1K
Beta
0.81
Float Shares
7.39M
Free Float %
81.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | -34.93% | -28.35% | +50.93% | +75.27% | +46.85% | -1.21% | -84.80% | -96.44% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (2 ratings, all time)
Buy
Price Targets & DCF
Current price
3.75
DCF (Unlevered)
1.92
-48.8%
DCF (Levered)
1.86
-50.5%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
50% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-53.30
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C-
Overall Score
1 / 5
Low
DCF Score
3 / 5
Medium
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-83.0%
-
EPS growth Biotechnology: +29.7%+20.4% Q1'26: +9.1% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-10,832.9%
-
EBIT margin Biotechnology: +0.0%-10,711.2%
-
ROIC Biotechnology: -16.1%— Q1'26: +0.0% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+4.3% Q1'26: +4.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00×
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|
| Revenue |
22.49M
est: 22.83M (-1.5%)
|
35.28M
est: 32.15M (+9.7%)
|
1.00M
est: 1.07M (-6.5%)
|
170.0K
est: 33.3K (+410.0%)
|
134.7K
134.7K – 134.7K
+304.2% YoY
|
5.00M
5.00M – 5.00M
+3,611.3% YoY
|
3.60M
3.60M – 3.60M
-28.0% YoY
|
45.00M
45.00M – 45.00M
+1,150.0% YoY
|
| EBITDA |
-93.44M
est: 13.70M (-782.1%)
|
-29.03M
est: 19.29M (-250.5%)
|
-22.24M
est: 214.0K (-10,490.2%)
|
-18.06M
est: 6.7K (-271,072.1%)
|
26.9K
26.9K – 26.9K
+304.2% YoY
|
1,000.0K
1,000.0K – 1,000.0K
+3,611.4% YoY
|
720.0K
720.0K – 720.0K
-28.0% YoY
|
9.00M
9.00M – 9.00M
+1,150.0% YoY
|
| EBIT |
-96.13M
est: 13.70M (-801.7%)
|
-29.48M
est: 19.29M (-252.8%)
|
-22.41M
est: 214.0K (-10,571.5%)
|
-18.21M
est: 6.7K (-273,262.3%)
|
26.9K
26.9K – 26.9K
+304.2% YoY
|
1,000.0K
1,000.0K – 1,000.0K
+3,611.4% YoY
|
720.0K
720.0K – 720.0K
-28.0% YoY
|
9.00M
9.00M – 9.00M
+1,150.0% YoY
|
| Net Income |
-80.89M
est: -1.52B (+94.7%)
|
-32.66M
est: -629.67M (+94.8%)
|
-19.99M
est: -22.73M (+12.1%)
|
-16.59M
est: -20.20M (+17.9%)
|
-8.34M
-8.34M – -8.34M
+58.7% YoY
|
-5.73M
-5.73M – -5.73M
+31.3% YoY
|
-8.51M
-8.51M – -8.51M
-48.5% YoY
|
—
— – —
+100.0% YoY
|
| SGA |
30.01M
est: 73.40M (-59.1%)
|
12.80M
est: 103.37M (-87.6%)
|
12.08M
est: 16.36M (-26.2%)
|
10.43M
est: 509.5K (+1,947.0%)
|
2.06M
2.06M – 2.06M
+304.2% YoY
|
76.43M
76.43M – 76.43M
+3,611.3% YoY
|
55.03M
55.03M – 55.03M
-28.0% YoY
|
687.85M
687.85M – 687.85M
+1,150.0% YoY
|
| EPS |
-250.12
est: -182.63 (-37.0%)
|
-74.81
est: -75.60 (+1.0%)
|
-2.40
est: -2.62 (+8.3%)
|
-1.91
est: -2.33 (+17.8%)
|
-0.96
-0.96 – -0.96
+58.7% YoY
|
-0.66
-0.66 – -0.66
+31.3% YoY
|
-0.98
-0.98 – -0.98
-48.5% YoY
|
—
— – —
+100.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-11 | C- | 1/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-07 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-06 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-05 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-04 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-05-01 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-30 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-29 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-28 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-27 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-24 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-23 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-22 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-21 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-20 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-17 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
| 2026-04-16 | C | 2/5 | 3/5 | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-15.59M
OE per share TTM
-1.78
Owner's Yield
-53.10%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
66.7%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
14
Total invested
2.18M
Insider transactions (90d)
0
Beneficial owners (>5%)
28
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | MM Asset Management Inc. | 5.14M | 9.99% | — | 5.14M | — | 5.14M | CO | Cayman Islands | 2021-02-22 | ↗ |
| 2 | MMCAP International Inc. SPC | 5.14M | 9.99% | — | 5.14M | — | 5.14M | CO | Cayman Islands | 2021-02-22 | ↗ |
| 3 | Finance Ltd | 4.09M | 10.90% | 4.09M | — | 4.09M | — | CO | People’s Republic of China | 2010-02-10 | ↗ |
| 4 | Mingsheng | 4.09M | 10.90% | — | 4.09M | — | — | IN | People’s Republic of China | 2010-02-10 | ↗ |
| 5 | Zhang | 4.09M | 10.90% | — | 4.09M | — | — | IN | People’s Republic of China | 2010-02-10 | ↗ |
| 6 | CVI Investments, Inc. | 3.00M | 5.10% | — | — | — | 3.00M | CO | Cayman Islands | 2021-02-24 | ↗ |
| 7 | Heights Capital Management, Inc. | 3.00M | 5.10% | — | — | — | 3.00M | CO | Cayman Islands | 2021-02-24 | ↗ |
| 8 | Mok King Yu | 1.27M | 13.48% | — | 1.27M | — | 1.27M | IN | Hong Kong SAR | 2016-09-26 | ↗ |
| 9 | Newhall Construction Limited | 1.27M | 13.48% | — | 1.27M | — | 1.27M | OO | Hong Kong SAR | 2016-09-26 | ↗ |
| 10 | 13-3127734 | 1.05M | 5.39% | 1.01M | — | 1.05M | — | HC | Delaware | 2021-02-10 | ↗ |
| 11 | 26-0385758 | 1.05M | 5.39% | 1.01M | — | 1.05M | — | IA | Delaware | 2021-02-10 | ↗ |
| 12 | Daniel B. Asher | 949.6K | 1.60% | — | 949.6K | — | 947.7K | HC, IN | United States of America | 2021-02-22 | ↗ |
| 13 | Intracoastal Capital LLC | 949.6K | 1.60% | — | 949.6K | — | 947.7K | OO | United States of America | 2021-02-22 | ↗ |
| 14 | Mitchell P. Kopin | 949.6K | 1.60% | — | 949.6K | — | 947.7K | HC, IN | United States of America | 2021-02-22 | ↗ |
| 15 | Armistice Capital Master Fund Ltd. | 763.5K | 6.00% | — | 763.5K | — | 763.5K | CO | Delaware | 2020-05-04 | ↗ |
| 16 | Armistice Capital, LLC | 763.5K | 6.00% | — | 763.5K | — | 763.5K | IA, OO | Delaware | 2020-05-04 | ↗ |
| 17 | Steven Boyd | 763.5K | 6.00% | — | 763.5K | — | 763.5K | HC, IN | Delaware | 2020-05-04 | ↗ |
| 18 | Sanford | 635.6K | 9.70% | — | 635.6K | — | — | CO | North Dakota, United States | 2016-09-21 | ↗ |
| 19 | Sanford Health | 635.6K | 9.70% | — | 635.6K | — | — | CO | South Dakota, United States | 2016-09-21 | ↗ |
| 20 | Catherine M. Vaczy | 475.3K | 5.40% | 475.3K | — | 475.3K | — | IN | United | 2009-09-10 | ↗ |
| 21 | GREENFIELD CHILDREN LLC | 430.9K | 2.60% | 430.9K | — | 430.9K | — | CO | FLORIDA | 2020-07-21 | ↗ |
| 22 | 20-0975900 | 375.0K | 9.19% | — | — | — | — | OO | : | 2007-08-21 | ↗ |
| 23 | John S. Clark II | 375.0K | 9.19% | — | — | — | — | IN | : | 2007-08-21 | ↗ |
| 24 | Robert W. Butts | 375.0K | 9.19% | — | — | — | — | IN | : | 2007-08-21 | ↗ |
| 25 | 14-1770168 | 374.8K | 7.90% | 374.8K | — | 374.8K | — | IA | New York | 2008-02-14 | ↗ |
| 26 | JESSE GREENFIELD | 348.7K | 2.11% | 348.7K | — | 348.7K | — | IN | FLORIDA | 2020-07-21 | ↗ |
| 27 | IAN GREENFIELD | 85.3K | 0.51% | 85.3K | — | 85.3K | — | IN | FLORIDA | 2020-07-21 | ↗ |
| 28 | JANA GREENFIELD | 53.2K | 0.32% | 53.2K | — | 53.2K | — | IN | FLORIDA | 2020-07-21 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
14
-11 vs prev Q
New positions
7
Closed positions
18
Increased
8
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 270.9K +395.0 (+0.1%) | 503.9K -204.9K (-28.9%) | 3.10% -0.043 pp | 0.00% +0.000 pp | USD3.88 -52.1% | 14 qtrs — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 123.7K +7.1K (+6.1%) | 230.1K -75.4K (-24.7%) | 1.42% +0.061 pp | 0.00% +0.000 pp | USD4.07 -54.3% | 14 qtrs — |
| 3 | BML CAPITAL MANAGEMENT, LLC | 73.3K -36.5K (-33.2%) | 136.4K -151.4K (-52.6%) | 0.84% -0.437 pp | 0.12% -0.146 pp | USD2.58 -27.9% | 13 qtrs — |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 64.4K +1.2K (+1.8%) | 119.9K -45.9K (-27.7%) | 0.74% +0.002 pp | 0.00% +0.000 pp | USD3.40 -45.3% | 14 qtrs — |
| 5 | BLACKROCK, INC. | 54.9K -33.0 (-0.1%) | 102.0K -41.8K (-29.0%) | 0.63% -0.010 pp | 0.00% +0.000 pp | USD3.00 -38.0% | 6 qtrs — |
| 6 | GROUND SWELL CAPITAL, LLC | 39.0K +15.2K (+64.0%) | 72.5K +10.2K (+16.4%) | 0.45% +0.170 pp | 0.15% +0.013 pp | USD2.32 -19.8% | 2 qtrs — |
| 7 | CERITY PARTNERS LLC | 12.2K +— (+0.0%) | 49.1K +18.4K (+59.9%) | 0.14% -0.002 pp | 0.00% +0.000 pp | USD2.90 -35.9% | 3 qtrs — |
| 8 | STATE STREET CORP | 14.3K +— (+0.0%) | 26.7K -10.9K (-29.0%) | 0.16% -0.003 pp | 0.00% +0.000 pp | USD4.63 -59.8% | 14 qtrs — |
| 9 | DIMENSIONAL FUND ADVISORS LP | 14.3K -6.7K (-32.0%) | 26.5K -28.4K (-51.7%) | 0.16% -0.080 pp | 0.00% +0.000 pp | USD3.16 -41.1% | 8 qtrs — |
| 10 | BANK OF AMERICA CORP /DE/ | 10.4K +1.0 (+0.0%) | 19.4K -7.9K (-29.0%) | 0.12% -0.002 pp | 0.00% +0.000 pp | USD2.20 -15.5% | 13 qtrs — |
| 11 | NORTHERN TRUST CORP | 10.3K +— (+0.0%) | 19.1K -7.8K (-29.0%) | 0.12% -0.002 pp | 0.00% +0.000 pp | USD2.35 -20.9% | 4 qtrs — |
| 12 | HIGHTOWER ADVISORS, LLC | 10.0K +— (+0.0%) | 18.7K -7.6K (-29.0%) | 0.11% -0.002 pp | 0.00% +0.000 pp | USD3.70 -49.7% | 11 qtrs — |
| 13 | ROYAL BANK OF CANADA | 5.9K +1.0 (+0.0%) | 11.0K -4.0K (-26.7%) | 0.07% -0.001 pp | 0.00% +0.000 pp | USD2.35 -20.9% | 4 qtrs — |
| 14 | INTERNATIONAL ASSETS INVESTMENT MANAGEMENT, LLC | 5.0K +5.0K (+100.0%) | 9.3K +9.3K (+100.0%) | 0.06% +0.057 pp | 0.00% +0.001 pp | USD1.86 +0.0% | 1 qtrs NEW |
| 15 | TOWER RESEARCH CAPITAL LLC (TRC) | 2.6K +881.0 (+52.7%) | 4.7K +369.0 (+8.4%) | 0.03% +0.010 pp | 0.00% +0.000 pp | USD2.48 -25.0% | 13 qtrs — |
| 16 | FOUNDERS CAPITAL MANAGEMENT | 1.7K -333.0 (-16.7%) | 3.1K -2.1K (-40.8%) | 0.02% -0.004 pp | 0.00% -0.001 pp | USD3.73 -50.1% | 14 qtrs — |
| 17 | CONNECTIVE CAPITAL MANAGEMENT, LLC | 1.0K +— (+0.0%) | 1.9K -772.0 (-29.0%) | 0.01% 0.000 pp | 0.00% -0.001 pp | USD2.62 -29.0% | 2 qtrs — |
| 18 | UBS GROUP AG | 871.00 +871.0 (+100.0%) | 1.6K +1.6K (+100.0%) | 0.01% +0.010 pp | 0.00% +0.000 pp | USD1.86 +0.0% | 14 qtrs — |
| 19 | NEWEDGE ADVISORS, LLC | 107.00 +107.0 (+100.0%) | 199.00 +199.0 (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD1.86 +0.0% | 1 qtrs NEW |
| 20 | ADVISOR GROUP HOLDINGS, INC. | 100.00 +100.0 (+100.0%) | 186.00 +186.0 (+100.0%) | 0.00% +0.001 pp | 0.00% +0.000 pp | USD1.86 +0.0% | 14 qtrs — |
| 21 | MORGAN STANLEY | 75.00 -133.0 (-63.9%) | 140.00 -405.0 (-74.3%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD3.77 -50.7% | 14 qtrs — |
| 22 | CHEVIOT VALUE MANAGEMENT, LLC | 3.00 +— (+0.0%) | 14.00 +6.0 (+75.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD2.33 -20.2% | 4 qtrs — |
| 23 | SBI SECURITIES CO., LTD. | 7.00 -133.0 (-95.0%) | 13.00 -354.0 (-96.5%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD2.86 -35.0% | 5 qtrs — |
| 24 | CITIGROUP INC | 1.00 +1.0 (+100.0%) | 2.00 +2.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.00 +86.0% | 1 qtrs NEW |
| 25 | FORTITUDE FAMILY OFFICE, LLC | 1.00 +1.0 (+100.0%) | 2.00 +2.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD1.00 +86.0% | 1 qtrs NEW |
| 26 | BARCLAYS PLC | — -7.0 (-100.0%) | — -21.0 (-100.0%) | 0.00% 0.000 pp | 0.00% +0.000 pp | USD— | 9 qtrs SOLD |
| 27 | XTX TOPCO LTD | — -11.1K (-100.0%) | — -29.1K (-100.0%) | 0.00% -0.129 pp | 0.00% -0.002 pp | USD— | 2 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
Held by 13 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Vanguard Extended Market ETF VXF | 0.00% | 255.5K | 0.05% |
| 2 | Vanguard U.S. Total Market Shares Index ETF VTS.AX | 0.00% | 1.3K | 0.03% |
| 3 | Vanguard U.S. Total Market Index ETF (CAD-hedged) VUS.TO | 0.00% | 267.37 | 0.17% |
| 4 | Vanguard U.S. Total Market Index ETF VUN.TO | 0.00% | 3.6K | 0.17% |
| 5 | Vanguard Total Stock Market ETF VTI | 0.00% | 618.5K | 0.03% |
| 6 | Dimensional - US Sustainability Core 1 ETF DFSU | 0.00% | 325.18 | 0.15% |
| 7 | Vanguard All-Equity ETF Portfolio VEQT.TO | 0.00% | 1.4K | 0.22% |
| 8 | Vanguard Growth ETF Portfolio VGRO.TO | 0.00% | 737.57 | 0.22% |
| 9 | Vanguard Balanced ETF Portfolio VBAL.TO | 0.00% | 297.95 | 0.22% |
| 10 | Vanguard Conservative ETF Portfolio VCNS.TO | 0.00% | 32.83 | 0.22% |
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.92
Neutral
Ratio by volume
3.00
Bullish
Buys
11
Sells
12
Shares acquired
259.9K
Shares disposed
42.8K
Cash buys
—
Cash sales
—
Net activity
+217,140
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-09 | Nisco James | Officer | A-Award | A | Common Stock | 15,000 | 0.00 | — | 38,491 | D | ↗ |
| 2026-01-09 | Mazzo David J | Director / Officer | A-Award | A | Common Stock | 81,000 | 0.00 | — | 352,986 | D | ↗ |
| 2026-01-09 | KLOSK STEVEN M | Director | A-Award | A | Common Stock | 30,456 | 0.00 | — | 95,815 | D | ↗ |
| 2026-01-09 | Imam Tariq | Officer | F-InKind | D | Common Stock | 1,401 | 1.97 | 2.8K | 38,178 | D | ↗ |
| 2026-01-09 | HENSON HEIDI | Director | A-Award | A | Common Stock | 30,456 | 0.00 | — | 85,725 | D | ↗ |
| 2026-01-09 | Flowers Cynthia Louise | Director | A-Award | A | Common Stock | 30,456 | 0.00 | — | 95,446 | D | ↗ |
| 2026-01-09 | Buck Kristen K | Officer | A-Award | A | Stock Option (Right to Buy) | 13,000 | 1.97 | 25.6K | 13,000 | D | ↗ |
| 2026-01-09 | BROWN GREGORY B | Director | A-Award | A | Common Stock | 30,456 | 0.00 | — | 95,659 | D | ↗ |
| 2026-01-09 | AZAB MOHAMMAD | Director | A-Award | A | Common Stock | 30,456 | 0.00 | — | 104,925 | D | ↗ |
| 2025-02-03 | Imam Tariq | Officer | — | — | Stock Option (Right to Buy) | 5,000 | 3.80 | 19.0K | 0 | D | ↗ |
| 2025-01-10 | Nisco James | Officer | F-InKind | D | Common Stock | 416 | 3.73 | 1.6K | 23,491 | D | ↗ |
| 2025-01-10 | Mazzo David J | Director / Officer | F-InKind | D | Common Stock | 3,106 | 3.73 | 11.6K | 264,690 | D | ↗ |
| 2025-01-10 | Imam Tariq | Officer | — | — | Stock Option (Right to Buy) | 1,466 | 13.76 | 20.2K | 0 | D | ↗ |
| 2025-01-10 | Buck Kristen K | Officer | F-InKind | D | Common Stock | 456 | 3.73 | 1.7K | 79,794 | D | ↗ |
| 2025-01-09 | Nisco James | Officer | F-InKind | D | Common Stock | 1,137 | 3.80 | 4.3K | 24,688 | D | ↗ |
| 2025-01-09 | Mazzo David J | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 40,000 | 3.80 | 152.0K | 40,000 | D | ↗ |
| 2025-01-09 | KLOSK STEVEN M | Director | A-Award | A | Common Stock | 15,789 | 0.00 | — | 65,359 | D | ↗ |
| 2025-01-09 | HENSON HEIDI | Director | A-Award | A | Common Stock | 15,789 | 0.00 | — | 55,269 | D | ↗ |
| 2025-01-09 | Flowers Cynthia Louise | Director | A-Award | A | Common Stock | 15,789 | 0.00 | — | 64,990 | D | ↗ |
| 2025-01-09 | Buck Kristen K | Officer | A-Award | A | Stock Option (Right to Buy) | 13,000 | 3.80 | 49.4K | 13,000 | D | ↗ |
| 2025-01-09 | BROWN GREGORY B | Director | A-Award | A | Common Stock | 15,789 | 0.00 | — | 65,203 | D | ↗ |
| 2025-01-09 | AZAB MOHAMMAD | Director | A-Award | A | Common Stock | 15,789 | 0.00 | — | 74,469 | D | ↗ |
| 2024-10-01 | Nisco James | Officer | F-InKind | D | Common Stock | 1,701 | 2.93 | 5.0K | 12,956 | D | ↗ |
| 2024-10-01 | Mazzo David J | Director / Officer | F-InKind | D | Common Stock | 26,964 | 2.93 | 79.0K | 211,834 | D | ↗ |
| 2024-10-01 | Buck Kristen K | Officer | F-InKind | D | Common Stock | 6,363 | 2.93 | 18.6K | 62,672 | D | ↗ |
| 2024-04-15 | Nisco James | Officer | — | D | Common Stock | 0 | 0.00 | — | 11,357 | — | ↗ |
| 2024-01-11 | Nisco James | Officer | — | D | Stock Option (Right to Buy) | 466 | 23.85 | 11.1K | 0 | — | ↗ |
| 2024-01-11 | Mazzo David J | Director / Officer | F-InKind | D | Common Stock | 1,026 | 2.99 | 3.1K | 174,766 | — | ↗ |
| 2024-01-11 | Imam Tariq | Officer | — | — | Stock Option (Right to Buy) | 466 | 23.85 | 11.1K | 0 | D | ↗ |
| 2024-01-10 | Mazzo David J | Director / Officer | F-InKind | D | Common Stock | 3,470 | 3.00 | 10.4K | 175,792 | — | ↗ |
| 2024-01-10 | Buck Kristen K | Officer | F-InKind | D | Common Stock | 512 | 3.00 | 1.5K | 54,035 | — | ↗ |
| 2024-01-09 | Mazzo David J | Director / Officer | A-Award | A | Common Stock | 94,000 | 0.00 | — | 199,308 | — | ↗ |
| 2024-01-09 | KLOSK STEVEN M | Director | A-Award | A | Common Stock | 19,480 | 0.00 | — | 49,570 | — | ↗ |
| 2024-01-09 | HENSON HEIDI | Director | A-Award | A | Common Stock | 19,480 | 0.00 | — | 39,480 | — | ↗ |
| 2024-01-09 | Flowers Cynthia Louise | Director | A-Award | A | Common Stock | 19,480 | 0.00 | — | 49,201 | — | ↗ |
| 2024-01-09 | Buck Kristen K | Officer | A-Award | A | Stock Option (Right to Buy) | 14,000 | 3.08 | 43.1K | 14,000 | — | ↗ |
| 2024-01-09 | BROWN GREGORY B | Director | A-Award | A | Common Stock | 19,480 | 0.00 | — | 49,414 | — | ↗ |
| 2024-01-09 | AZAB MOHAMMAD | Director | A-Award | A | Common Stock | 19,480 | 0.00 | — | 58,680 | — | ↗ |
| 2023-09-01 | Buck Kristen K | Officer | F-InKind | D | Common Stock | 2,908 | 2.18 | 6.3K | 32,915 | — | ↗ |
| 2023-01-13 | Nisco James | Officer | — | D | Stock Option (Right to Buy) | 201 | 49.20 | 9.9K | 0 | — | ↗ |
| 2023-01-13 | Mazzo David J | Officer | F-InKind | D | Common Stock | 397 | 3.65 | 1.4K | 96,543 | — | ↗ |
| 2023-01-13 | Imam Tariq | Officer | — | — | Stock Option (Right to Buy) | 480 | 49.20 | 23.6K | 0 | D | ↗ |
| 2023-01-11 | Mazzo David J | Officer | F-InKind | D | Common Stock | 1,030 | 3.20 | 3.3K | 96,940 | — | ↗ |
| 2023-01-10 | Mazzo David J | Officer | F-InKind | D | Common Stock | 3,470 | 3.20 | 11.1K | 97,970 | — | ↗ |
| 2023-01-10 | Buck Kristen K | Officer | F-InKind | D | Common Stock | 512 | 3.20 | 1.6K | 35,823 | — | ↗ |
| 2023-01-09 | Slack David W. | Officer | A-Award | A | Stock Options (Right to Buy) | 12,000 | 0.00 | — | 12,000 | — | ↗ |
| 2023-01-09 | Ruoslahti Erkki | Director | A-Award | A | Common Stock | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2023-01-09 | Mazzo David J | Officer | F-InKind | D | Common Stock | 7,845 | 3.00 | 23.5K | 101,440 | — | ↗ |
| 2023-01-09 | KLOSK STEVEN M | Director | A-Award | A | Common Stock | 20,000 | 0.00 | — | 30,090 | — | ↗ |
| 2023-01-09 | HENSON HEIDI | Director | A-Award | A | Common Stock | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2023-01-09 | Flowers Cynthia Louise | Director | A-Award | A | Common Stock | 20,000 | 0.00 | — | 29,721 | — | ↗ |
| 2023-01-09 | Buck Kristen K | Officer | A-Award | A | Stock Options (Right to Buy) | 9,000 | 0.00 | — | 9,000 | — | ↗ |
| 2023-01-09 | BROWN GREGORY B | Director | A-Award | A | Common Stock | 20,000 | 0.00 | — | 29,934 | — | ↗ |
| 2023-01-09 | AZAB MOHAMMAD | Director | A-Award | A | Common Stock | 20,000 | 0.00 | — | 39,200 | — | ↗ |
| 2022-09-15 | Ruoslahti Erkki | Director | — | I | Common Stock | 0 | 0.00 | — | 1,171,144 | — | ↗ |
| 2022-09-15 | AZAB MOHAMMAD | Director | A-Award | A | Common Stock | 19,200 | 6.25 | 120.0K | 19,200 | — | ↗ |
| 2022-06-09 | HENSON HEIDI | Director | — | D | Stock Option (Right to Buy) | 10,676 | 7.52 | 80.3K | 0 | — | ↗ |
| 2022-01-14 | Nisco James | Officer | — | D | Stock Option (Right to Buy) | 168 | 74.25 | 12.5K | 0 | — | ↗ |
| 2022-01-14 | Mazzo David J | Director / Officer | F-InKind | D | Common Stock | 6,611 | 0.82 | 5.4K | 631,065 | — | ↗ |
| 2022-01-14 | Imam Tariq | Officer | — | — | Stock Option (Right to Buy) | 168 | 74.25 | 12.5K | 0 | D | ↗ |
| 2022-01-14 | Girolamo Todd C | Officer | F-InKind | D | Common Stock | 2,158 | 0.82 | 1.8K | 160,827 | — | ↗ |
| 2022-01-13 | Mazzo David J | Director / Officer | F-InKind | D | Common Stock | 6,471 | 0.81 | 5.2K | 637,676 | — | ↗ |
| 2022-01-13 | Girolamo Todd C | Officer | F-InKind | D | Common Stock | 2,563 | 0.81 | 2.1K | 162,985 | — | ↗ |
| 2022-01-11 | Mazzo David J | Director / Officer | F-InKind | D | Common Stock | 16,740 | 0.87 | 14.5K | 644,147 | — | ↗ |
| 2022-01-11 | Girolamo Todd C | Officer | F-InKind | D | Common Stock | 4,722 | 0.87 | 4.1K | 165,548 | — | ↗ |
| 2022-01-10 | Whitaker Anne Clem | Director | A-Award | A | Common Stock | 65,430 | 0.00 | — | 182,635 | — | ↗ |
| 2022-01-10 | TRABER PETER G | Director | A-Award | A | Common Stock | 65,430 | 0.00 | — | 149,190 | — | ↗ |
| 2022-01-10 | Mazzo David J | Director / Officer | A-Award | A | Common Stock | 401,000 | 0.00 | — | 717,297 | — | ↗ |
| 2022-01-10 | MYERS STEVEN S | Director | A-Award | A | Common Stock | 65,430 | 0.00 | — | 212,269 | — | ↗ |
| 2022-01-10 | KLOSK STEVEN M | Director | A-Award | A | Common Stock | 65,430 | 0.00 | — | 151,390 | — | ↗ |
| 2022-01-10 | Girolamo Todd C | Officer | A-Award | A | Stock Option (Right to Buy) | 65,000 | 0.92 | 59.6K | 65,000 | — | ↗ |
| 2022-01-10 | Flowers Cynthia Louise | Director | A-Award | A | Common Stock | 65,430 | 0.00 | — | 145,847 | — | ↗ |
| 2022-01-10 | Davidson Michael H. | Director | A-Award | A | Common Stock | 65,430 | 0.00 | — | 209,753 | — | ↗ |
| 2022-01-10 | Buck Kristen K | Officer | A-Award | A | Stock Option (Right to Buy) | 32,500 | 0.92 | 29.8K | 32,500 | — | ↗ |
| 2022-01-10 | BROWN GREGORY B | Director | A-Award | A | Common Stock | 65,430 | 0.00 | — | 149,040 | — | ↗ |
| 2021-12-29 | Slack David W. | Director / Officer | — | D | Stock Option (Right to Buy) | 244,213 | 3.60 | 879.2K | 0 | — | ↗ |
| 2021-12-08 | MYERS STEVEN S | Director | P-Purchase | A | Common Stock | 33,785 | 0.89 | 30.2K | 146,839 | — | ↗ |
| 2021-09-01 | Buck Kristen K | Officer | A-Award | A | Stock Option (Right to Buy) | 1,137,915 | 1.28 | 1.46M | 1,137,915 | — | ↗ |
| 2021-03-31 | Slack David W. | Director / Officer | — | D | Stock Option (Right to Buy) | 10,676 | 4.22 | 45.1K | 0 | — | ↗ |
| 2021-03-31 | Ruoslahti Erkki | Director | — | D | Stock Option (Right to Buy) | 53,380 | 3.60 | 192.2K | 0 | — | ↗ |
| 2021-03-31 | HENSON HEIDI | Director | — | D | Stock Option (Right to Buy) | 10,676 | 3.60 | 38.4K | 0 | — | ↗ |
| 2021-01-14 | Mazzo David J | Director / Officer | F-InKind | D | Common Stock | 5,936 | 1.56 | 9.3K | 299,505 | — | ↗ |
| 2021-01-13 | Mazzo David J | Director / Officer | F-InKind | D | Common Stock | 6,425 | 1.55 | 10.0K | 305,441 | — | ↗ |
| 2021-01-08 | Nisco James | Officer | — | D | Stock Option (Right to Buy) | 140 | 56.85 | 8.0K | 0 | — | ↗ |
| 2021-01-08 | Imam Tariq | Officer | — | — | Stock Option (Right to Buy) | 96 | 56.85 | 5.5K | 0 | D | ↗ |
| 2020-01-09 | Nisco James | Officer | — | D | Stock Option (Right to Buy) | 39 | 53.10 | 2.1K | 0 | — | ↗ |
| 2019-11-30 | Ruoslahti Erkki | Director | — | D | Stock Option (Right to Buy) | 53,380 | 4.22 | 225.3K | 0 | — | ↗ |
| 2019-07-31 | HENSON HEIDI | Director | — | D | Stock Option (Right to Buy) | 10,676 | 4.22 | 45.1K | 0 | — | ↗ |
| 2019-01-25 | Nisco James | Officer | — | D | Stock Option (Right to Buy) | 33 | 94.50 | 3.1K | 0 | — | ↗ |
| 2018-06-02 | Nisco James | Officer | — | D | Stock Option (Right to Buy) | 66 | 339.00 | 22.4K | 0 | — | ↗ |
| 2017-05-18 | Imam Tariq | Officer | — | — | Stock Option (Right to Buy) | 14 | 53.10 | 743.40 | 0 | D | ↗ |
| 2016-09-29 | Nisco James | Officer | — | D | Stock Option (Right to Buy) | 398 | 71.55 | 28.5K | 0 | — | ↗ |
| 2016-03-23 | Nisco James | Officer | — | D | Stock Option (Right to Buy) | 64 | 580.50 | 37.2K | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-7.0K
Shares Outstanding
9.11M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2024 | David J. Mazzo, President and Chief Executive Officer | 703.0K | 387.9K | 468.2K | 101.9K | — | 30.3K | 1.69M | 33.71% | ↗ |
| 2 | 2024 | Kristen K. Buck, M.D, Executive Vice President of Research & Development and Chief Medical Officer | 597.4K | 299.7K | 129.4K | 30.4K | — | 8.3K | 1.07M | 15.00% | ↗ |
| 3 | 2024 | James Nisco, Senior Vice President, Finance and Treasury and Chief Accounting Officer | 341.9K | 122.5K | 34.8K | 8.7K | — | 8.3K | 516.2K | 8.42% | ↗ |
| 4 | 2023 | David J. Mazzo, President and Chief Executive Officer | 675.9K | 382.3K | 258.0K | 61.9K | — | 30.3K | 1.41M | 22.72% | ↗ |
| 5 | 2023 | David Slack, Former President and Chief Business Officer | 159.7K | — | 108.0K | 171.5K | — | 774.2K | 1.21M | 23.04% | ↗ |
| 6 | 2023 | Kristen K. Buck, M.D, Executive Vice President of Research & Development and Chief Medical Officer | 574.4K | 293.5K | 75.0K | 18.6K | — | 8.3K | 969.8K | 9.65% | ↗ |
| 7 | 2023 | James Nisco, Senior Vice President, Finance and Treasury and Chief Accounting Officer | 307.5K | 94.1K | 22.5K | 6.2K | — | 8.3K | 438.6K | 6.54% | ↗ |
| 8 | 2022 | David J. Mazzo, Chief Executive Officer | 650.4K | 482.3K | 643.0K | 123.9K | — | 30.3K | 1.93M | 39.74% | ↗ |
| 9 | 2022 | David J. Mazzo, President and Chief Executive Officer | 650.4K | 482.3K | 643.0K | 123.9K | — | 30.3K | 1.93M | 39.74% | ↗ |
| 10 | 2022 | Kristen K. Buck, M.D, Executive Vice President of Research & Development and Chief Medical Officer | 553.8K | 376.4K | 165.6K | 20.1K | — | 8.3K | 1.12M | 16.52% | ↗ |
| 11 | 2022 | David Slack, Former President and Chief Business Officer | 134.2K | 161.0K | — | — | — | 21.0K | 316.2K | 0.00% | ↗ |
| 12 | 2021 | Kristen K. Buck, M.D, Executive Vice President of Research & Development and Chief Medical Officer | 183.3K | 275.0K | 400.0K | 1.00M | — | — | 1.86M | 75.34% | ↗ |
| 13 | 2021 | David J. Mazzo, Chief Executive Officer | 631.5K | 295.9K | 313.2K | 64.3K | — | 30.3K | 1.34M | 28.27% | ↗ |
| 14 | 2020 | David J. Mazzo, President and Chief Executive Officer | 613.1K | 329.6K | 235.8K | 226.3K | — | 30.3K | 1.44M | 32.20% | ↗ |
| 15 | 2020 | Douglas Losordo, Former Chief Medical Officer | 412.4K | — | 103.7K | 95.1K | — | 101.7K | 712.9K | 27.89% | ↗ |
| 16 | 2020 | Todd Girolamo General Counsel and Corporate Secretary | 333.4K | 114.8K | 103.7K | 95.1K | — | 8.3K | 655.2K | 30.34% | ↗ |
| 17 | 2020 | Joseph Talamo, Former Chief Financial Officer | 223.4K | — | 103.7K | 95.1K | — | 72.9K | 495.1K | 40.15% | ↗ |
| 18 | 2020 | William K. Sietsema, Ph.D. Vice President, Global Regulatory Affairs | 273.6K | 70.3K | 26.0K | 23.6K | — | 6.7K | 400.2K | 12.40% | ↗ |
| 19 | 2019 | David J. Mazzo, President and Chief Executive Officer | 596.7K | 279.0K | 401.0K | 230.0K | — | 33.0K | 1.54M | 40.98% | ↗ |
| 20 | 2019 | Douglas Losordo, Former Chief Medical Officer | 443.4K | 150.8K | 202.0K | 77.8K | — | 16.1K | 890.0K | 31.43% | ↗ |
| 21 | 2019 | Douglas Losordo, Chief Medical Officer | 443.4K | 150.8K | 202.0K | 77.8K | — | 16.1K | 890.0K | 31.43% | ↗ |
| 22 | 2019 | Joseph Talamo, Chief Financial Officer | 338.1K | 100.6K | 152.0K | 77.8K | — | 8.3K | 676.6K | 33.95% | ↗ |
| 23 | 2019 | Joseph Talamo, Former Chief Financial Officer | 338.1K | 100.6K | 152.0K | 77.8K | — | 8.3K | 676.6K | 33.95% | ↗ |
| 24 | 2019 | Todd Girolamo General Counsel and Corporate Secretary | 323.2K | 96.5K | 152.0K | 77.8K | — | 8.3K | 657.7K | 34.93% | ↗ |
| 25 | 2019 | William K. Sietsema, Ph.D. Vice President, Global Regulatory Affairs | 263.9K | 62.7K | 37.9K | 19.4K | — | 6.3K | 390.2K | 14.69% | ↗ |
| 26 | 2018 | David J. Mazzo, President and Chief Executive Officer | 593.8K | 357.7K | 575.4K | 339.7K | — | 25.6K | 1.89M | 48.36% | ↗ |
| 27 | 2018 | Robert Preti, Former President and Chief Scientific Officer of PCT | — | — | — | — | — | 1.76M | 1.76M | 0.00% | ↗ |
| 28 | 2018 | Douglas Losordo, Chief Medical Officer | 441.3K | 189.3K | 229.8K | 135.9K | — | 16.1K | 1.01M | 36.12% | ↗ |
| 29 | 2018 | Joseph Talamo, Chief Financial Officer | 334.7K | 126.3K | 229.8K | 135.9K | — | 8.3K | 835.0K | 43.80% | ↗ |
| 30 | 2017 | Robert Preti, Former President and Chief Scientific Officer of PCT | 193.4K | 175.0K | — | — | — | 1.92M | 2.28M | 0.00% | ↗ |
| 31 | 2017 | David J. Mazzo, President and Chief Executive Officer | 576.5K | 346.5K | 117.9K | 116.0K | — | 26.0K | 1.18M | 19.77% | ↗ |
| 32 | 2017 | Douglas Losordo, Chief Medical Officer | 428.4K | 348.5K | 205.0K | 46.4K | — | — | 1.03M | 24.44% | ↗ |
| 33 | 2017 | Joseph Talamo, Chief Financial Officer | 316.1K | 103.6K | 47.1K | 46.4K | — | 8.1K | 521.3K | 17.93% | ↗ |
| 34 | 2016 | David J. Mazzo, President and Chief Executive Officer | 559.5K | 480.6K | 133.2K | 287.6K | — | 26.9K | 1.49M | 28.28% | ↗ |
| 35 | 2016 | Robert Preti, Former President and Chief Scientific Officer of PCT | 476.8K | 561.3K | 47.6K | 110.2K | — | 5.9K | 1.20M | 13.13% | ↗ |
| 36 | 2016 | Douglas Losordo, Chief Medical Officer | 415.8K | 182.8K | 53.8K | 100.0K | — | 7.9K | 760.3K | 20.23% | ↗ |
| 37 | 2016 | Joseph Talamo, Chief Financial Officer | 307.0K | 137.0K | 47.6K | 89.3K | — | 8.0K | 588.9K | 23.25% | ↗ |
| 38 | 2015 | Robin Smith, Former Chief Executive Officer | 237.4K | 243.1K | 156.8K | 950.8K | — | 1.26M | 2.85M | 38.82% | ↗ |
| 39 | 2015 | David J. Mazzo, Chief Executive Officer | 541.4K | — | 736.0K | 883.1K | — | 665.1K | 2.83M | 57.30% | ↗ |
| 40 | 2015 | Robert Vaters, Former President and Chief Financial Officer | 320.4K | — | 397.9K | 883.1K | — | 837.2K | 2.44M | 52.53% | ↗ |
| 41 | 2015 | Robert Preti, President and Chief Scientific Officer of PCT | 410.0K | — | — | 316.7K | — | 4.9K | 731.6K | 43.28% | ↗ |
| 42 | 2015 | Douglas Losordo, Chief Medical Officer | 405.0K | — | 15.9K | 145.5K | — | 17.8K | 584.2K | 27.62% | ↗ |
| 43 | 2015 | Joseph Talamo, Chief Financial Officer | 261.9K | — | 50.9K | 72.4K | — | 46.5K | 431.7K | 28.56% | ↗ |
| 44 | 2015 | Andrew Pecora, Former Chief Visionary Officer | 162.5K | — | 22.6K | 181.1K | — | 23.5K | 389.6K | 52.28% | ↗ |
| 45 | 2015 | Robert Dickey IV, Former Chief Financial Officer | 2.3K | — | — | — | — | 226.9K | 229.3K | 0.00% | ↗ |
| 46 | 2014 | Robin Smith, Former Chief Executive Officer | 545.0K | 392.4K | 730.4K | 1.09M | — | 559.7K | 3.32M | 54.92% | ↗ |
| 47 | 2014 | Andrew Pecora, Former Chief Visionary Officer | 240.0K | — | 310.5K | 544.0K | — | 322.3K | 1.42M | 60.31% | ↗ |
| 48 | 2014 | Robert Preti, President and Chief Scientific Officer of PCT | 364.0K | 54.6K | 39.5K | 599.7K | — | 22.6K | 1.08M | 59.17% | ↗ |
| 49 | 2014 | Douglas Losordo, Chief Medical Officer | 385.0K | 60.2K | 101.5K | 365.7K | — | 60.3K | 972.7K | 48.03% | ↗ |
| 50 | 2014 | Robert Dickey IV, Former Chief Financial Officer | 310.0K | 23.3K | 39.1K | 287.4K | — | 60.7K | 720.5K | 45.33% | ↗ |
| 51 | 2014 | Joseph Talamo, Chief Financial Officer | 227.7K | 42.7K | 39.1K | 287.4K | — | 22.8K | 619.8K | 52.69% | ↗ |
| 52 | 2013 | Robin Smith, Former Chief Executive Officer | 495.0K | 450.0K | — | 249.7K | — | 40.8K | 1.24M | 20.21% | ↗ |
| 53 | 2013 | Andrew Pecora, Former Chief Visionary Officer | 221.5K | 365.0K | — | 286.5K | — | — | 873.0K | 32.81% | ↗ |
| 54 | 2013 | Douglas Losordo, Chief Medical Officer | 291.5K | 40.0K | 145.8K | 343.1K | — | 30.8K | 851.2K | 57.43% | ↗ |
| 55 | 2013 | Robert Preti, President and Chief Scientific Officer of PCT | 349.2K | 145.0K | — | 143.2K | — | — | 637.5K | 22.47% | ↗ |
| 56 | 2013 | Robert Dickey IV, Former Chief Financial Officer | 150.6K | 40.0K | — | 229.5K | — | 15.3K | 435.4K | 52.70% | ↗ |
| 57 | 2013 | Joseph Talamo, Chief Financial Officer | 219.6K | 100.0K | — | 107.4K | — | — | 427.0K | 25.16% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| David J. Mazzo | President, Chief Executive Officer & Director | 735.5K | — |
| Kristen K. Buck | Executive Vice President of R&D and Chief Medical Officer | 607.6K | — |
| James Nisco | Senior Vice President of Finance, Treasurer, CAO & Principal Financial and Accounting Officer | 358.3K | male |
| William K. Sietsema | Vice President of Global Regulatory Affairs | 350.6K | — |
| John D. Menditto | Vice President of Investor Relations & Corporate Communications | — | male |
| Gregory S. Berkin | Chief Information & Data Protection Officer | — | male |
| Tariq Imam | Senior Vice President of Business Development & Operations and General Counsel | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for LSTA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
